Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™

Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. Here we show that a combination of monoclonal antibodies (ZMapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal haemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use.

[1]  H. J. Channon,et al.  The effect of various fats in the production of dietary fatty livers. , 1936, The Biochemical journal.

[2]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[3]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[4]  P. Jahrling,et al.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. , 1999, The Journal of infectious diseases.

[5]  R. Colebunders,et al.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. , 1999, The Journal of infectious diseases.

[6]  P. Jahrling,et al.  Pathogenesis of experimental Ebola virus infection in guinea pigs. , 1999, The Journal of infectious diseases.

[7]  R. Colebunders,et al.  Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[8]  J. Wilson,et al.  Epitopes involved in antibody-mediated protection from Ebola virus. , 2000, Science.

[9]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[10]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[11]  A. Chinnaiyan,et al.  Integrative analysis of the cancer transcriptome , 2005, Nature Genetics.

[12]  W. Filipowicz,et al.  Inhibition of Translational Initiation by Let-7 MicroRNA in Human Cells , 2005, Science.

[13]  C. Burge,et al.  The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution , 2005, Science.

[14]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[15]  P. Sarnow,et al.  Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.

[16]  Anton J. Enright,et al.  Zebrafish MiR-430 Promotes Deadenylation and Clearance of Maternal mRNAs , 2006, Science.

[17]  Mark Graham,et al.  miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. , 2006, Cell metabolism.

[18]  Carola Engler,et al.  Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors , 2006, Proceedings of the National Academy of Sciences.

[19]  L. Fernando,et al.  Effective Post-Exposure Treatment of Ebola Infection , 2007, PLoS pathogens.

[20]  P. Jahrling,et al.  Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. , 2007, The Journal of infectious diseases.

[21]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[22]  L. Lim,et al.  MicroRNA targeting specificity in mammals: determinants beyond seed pairing. , 2007, Molecular cell.

[23]  Margaret S. Ebert,et al.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.

[24]  M. Todesco,et al.  Target mimicry provides a new mechanism for regulation of microRNA activity , 2007, Nature Genetics.

[25]  E. Izaurralde,et al.  Getting to the Root of miRNA-Mediated Gene Silencing , 2008, Cell.

[26]  Benjamin Jeffs,et al.  Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. , 2008, Antiviral research.

[27]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[28]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[29]  Hervé Seitz,et al.  Redefining MicroRNA Targets , 2009, Current Biology.

[30]  Justin J. Cassidy,et al.  A MicroRNA Imparts Robustness against Environmental Fluctuation during Development , 2009, Cell.

[31]  T. Tuschl,et al.  Absolute quantification of microRNAs by using a universal reference. , 2009, RNA.

[32]  Hsien-Da Huang,et al.  MicroRNA‐122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma , 2009, Hepatology.

[33]  C. Sander,et al.  Target mRNA abundance dilutes microRNA and siRNA activity , 2010, Molecular systems biology.

[34]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[35]  Zhiping Weng,et al.  Target RNA–Directed Trimming and Tailing of Small Silencing RNAs , 2010, Science.

[36]  Scott B. Dewell,et al.  Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIP , 2010, Cell.

[37]  P. Pandolfi,et al.  A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010, Nature.

[38]  A. Abbott,et al.  Loss of Individual MicroRNAs Causes Mutant Phenotypes in Sensitized Genetic Backgrounds in C. elegans , 2010, Current Biology.

[39]  P. Iversen,et al.  Advanced antisense therapies for postexposure protection against lethal filovirus infections , 2010, Nature Medicine.

[40]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[41]  Grace X. Y. Zheng,et al.  MicroRNAs can generate thresholds in target gene expression , 2011, Nature Genetics.

[42]  Ferdinando Di Cunto,et al.  Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs , 2011, Cell.

[43]  D. Cacchiarelli,et al.  A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA , 2011, Cell.

[44]  N. Bohorova,et al.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant , 2011, Proceedings of the National Academy of Sciences.

[45]  P. Pandolfi,et al.  In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma , 2011, Cell.

[46]  Ling Fang,et al.  Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis , 2010, Nucleic acids research.

[47]  X. Qiu,et al.  Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. , 2011, Clinical immunology.

[48]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[49]  D. Bartel,et al.  Weak Seed-Pairing Stability and High Target-Site Abundance Decrease the Proficiency of lsy-6 and Other miRNAs , 2011, Nature Structural &Molecular Biology.

[50]  X. Qiu,et al.  Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates , 2012, Science Translational Medicine.

[51]  Lisa Hensley,et al.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques , 2012, Proceedings of the National Academy of Sciences.

[52]  X. Qiu,et al.  Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection , 2012, PLoS neglected tropical diseases.

[53]  J. Mendell,et al.  MicroRNAs in Stress Signaling and Human Disease , 2012, Cell.

[54]  Peter B. Jahrling,et al.  Clinical Management of Filovirus-Infected Patients , 2012, Viruses.

[55]  M. Brady,et al.  PCB 126 and Other Dioxin-Like PCBs Specifically Suppress Hepatic PEPCK Expression via the Aryl Hydrocarbon Receptor , 2012, PloS one.

[56]  X. Qiu,et al.  Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.

[57]  C. Fabián Flores-Jasso,et al.  Argonaute Divides Its RNA Guide into Domains with Distinct Functions and RNA-Binding Properties , 2012, Cell.

[58]  R. Sachidanandam,et al.  High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries , 2012, Nature Methods.

[59]  Majidat A. Muhammad,et al.  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease , 2012, Proceedings of the National Academy of Sciences.

[60]  R. Zecchina,et al.  Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments , 2013, Proceedings of the National Academy of Sciences.

[61]  Joshua C. Johnson,et al.  Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail , 2013, Science Translational Medicine.

[62]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[63]  J. Kjems,et al.  Natural RNA circles function as efficient microRNA sponges , 2013, Nature.

[64]  Sebastian D. Mackowiak,et al.  Circular RNAs are a large class of animal RNAs with regulatory potency , 2013, Nature.

[65]  M. Katze,et al.  Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.

[66]  Weining Yang,et al.  Versican 3′‐untranslated region (3′‐UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  X. Qiu,et al.  mAbs and Ad-Vectored IFN-α Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms , 2013, Science Translational Medicine.

[68]  X. Qiu,et al.  Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb , 2013, Scientific Reports.

[69]  Matteo Figliuzzi,et al.  MicroRNAs as a selective channel of communication between competing RNAs: a steady-state theory. , 2012, Biophysical journal.

[70]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[71]  X. Qiu,et al.  Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents , 2014, Vaccine.

[72]  王淳理,et al.  伊波拉病毒感染(Ebola Virus Disease, EVD)及防治工作 , 2015 .